These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30174587)

  • 21. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies.
    Iqbal K; Grundke-Iqbal I
    Curr Drug Targets; 2004 Aug; 5(6):495-502. PubMed ID: 15270196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathological Changes of Tau Related to Alzheimer's Disease.
    Chu D; Liu F
    ACS Chem Neurosci; 2019 Feb; 10(2):931-944. PubMed ID: 30346708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo.
    Domise M; Didier S; Marinangeli C; Zhao H; Chandakkar P; Buée L; Viollet B; Davies P; Marambaud P; Vingtdeux V
    Sci Rep; 2016 May; 6():26758. PubMed ID: 27230293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
    Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain.
    Guo C; Wang P; Zhong ML; Wang T; Huang XS; Li JY; Wang ZY
    Neurochem Int; 2013 Jan; 62(2):165-72. PubMed ID: 23262393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies.
    Gao Y; Tan L; Yu JT; Tan L
    Curr Alzheimer Res; 2018; 15(3):283-300. PubMed ID: 28413986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of mouse model exhibiting neurofibrillary changes].
    Takashima A
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1111-2. PubMed ID: 12235811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro aggregation assays using hyperphosphorylated tau protein.
    Sui D; Liu M; Kuo MH
    J Vis Exp; 2015 Jan; (95):e51537. PubMed ID: 25590418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Super-Resolution Imaging Uncovers Nanoscale Tau Aggregate Hyperphosphorylation Patterns in Human Alzheimer's Disease Brain Tissue.
    Santiago-Ruiz AN; Hugelier S; Bond CR; Lee EB; Lakadamyali M
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology.
    Sepulveda-Diaz JE; Alavi Naini SM; Huynh MB; Ouidja MO; Yanicostas C; Chantepie S; Villares J; Lamari F; Jospin E; van Kuppevelt TH; Mensah-Nyagan AG; Raisman-Vozari R; Soussi-Yanicostas N; Papy-Garcia D
    Brain; 2015 May; 138(Pt 5):1339-54. PubMed ID: 25842390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
    Wang JZ; Grundke-Iqbal I; Iqbal K
    Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
    Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
    J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Protein Phosphatase-2A (PP2A) by I1PP2A Leads to Hyperphosphorylation of Tau, Neurodegeneration, and Cognitive Impairment in Rats.
    Wang X; Blanchard J; Tung YC; Grundke-Iqbal I; Iqbal K
    J Alzheimers Dis; 2015; 45(2):423-35. PubMed ID: 25589718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Okadaic acid induced neurotoxicity: an emerging tool to study Alzheimer's disease pathology.
    Kamat PK; Rai S; Nath C
    Neurotoxicology; 2013 Jul; 37():163-72. PubMed ID: 23688530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: clinical relevance in Alzheimer's disease.
    Kumar P; Jha NK; Jha SK; Ramani K; Ambasta RK
    J Alzheimers Dis; 2015; 43(2):341-61. PubMed ID: 25096626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.
    Fan SJ; Huang FI; Liou JP; Yang CR
    Cell Death Dis; 2018 May; 9(6):655. PubMed ID: 29844403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
    Zhang Q; Zhang X; Sun A
    Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tau Assembly into Filaments.
    Pérez M; Cuadros R; Medina M
    Methods Mol Biol; 2018; 1779():447-461. PubMed ID: 29886549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.